申请人:Takeda Pharmaceutical Company Limited
公开号:US08153694B2
公开(公告)日:2012-04-10
A compound of the formula (I):
wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonist activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
公式(I)的化合物:其中每个符号如描述中所定义,其盐和前药,意外地具有优越的GPR40受体激动剂活性和作为药物产品的优越性能,如稳定性等,并且可以是安全有效的药物剂型,用于哺乳动物的GPR40受体相关病理或疾病的预防或治疗。